Table 2.
Clinical and serological characteristics of the study subgroups.
| Primary APS | Secondary APS | p-Values | OR (95% CI) | ||
|---|---|---|---|---|---|
| Number of patients | 30 | 42 | |||
| Gender | Male | 6 | 4 | 0.21 | 0.42 (0.10–1.64) |
| Female | 24 | 38 | |||
| Deep venous thrombosis | 14 | 16 | 0.46 | 0.70 (0.27–1.81) | |
| Recurrent deep venous thrombosis | 7 | 4 | 0.11 | 0.34 (0.09–1.31) | |
| Arterial thrombosis | 7 | 17 | 0.13 | 2.23 (0.78–6.36) | |
| Recurrent arterial thrombosis | 1 | 8 | 0.07 | 6.82 (0.80–57.82) | |
| Obstetric morbidity | 6 | 11 | 0.54 | 1.41 (0.45–4.38) | |
| Deep venous thrombosis + Arterial thrombosis | 0 | 6 | 0.22 | 3.91 (0.43–35.41) | |
| Deep venous thrombosis + Obstetric morbidity | 1 | 3 | 0.49 | 2.23 (0.22–22.55) | |
| Arterial thrombosis + Obstetric morbidity | 0 | 3 | 0.49 | 2.23 (0.22–22.55) | |
| Deep venous thrombosis + Arterial thrombosis + Obstetric morbidity | 0 | 2 | 0.56 | 1.05 (0.98–1.12) | |
| Non-thrombotic manifestations (such as livedo, vegetation, migraine, convulsions) | 11 | 14 | 0.76 | 0.86 (0.32–2.30) | |
| Serology at the time of diagnosis | aCL | 6 | 9 | 0.88 | 1.09 (0.34–3.47) |
| aβ2GPI | 9 | 10 | 0.55 | 0.72 (0.25–2.09) | |
| LAC | 30 | 42 | |||
| aCL + aβ2GPI | 2 | 5 | 0.46 | 1.89 (0.34–10.47) | |
| aCL + LAC | 6 | 9 | 0.88 | 1.09 (0.34–3.47) | |
| aβ2GPI + LAC | 9 | 10 | 0.55 | 0.72 (0.25–2.09) | |
APS—antiphospholipid syndrome; aCL—anti-cardiolipin antibodies; aβ2GPI—anti-β2 glycoprotein I antibodies; LAC—lupus anticoagulant.